|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6980 EUR | +36.59% |
|
+14.05% | -54.56% |
| 07-13 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 07-10 | AB Science streamlines its portfolio and refocuses on two molecules |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AB SCIENCE | Specialty & Advanced Pharmaceuticals | +36.59% | +14.05% | -54.56% | -49.71% | -95.36% | 46.55M |
- Stock Market
- Stocks
- AB Stock
- Charts AB Science
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
















